Skip to main content

Birmingham/Solihull CCG

Response from Medicines Management

You are perfectly correct that the national intent is of no great surprise and I am sure that you aware that we have advanced plans to release our policy statements on both Flash and Continuous Glucose Monitoring.  We have always aimed to release them in advance of April and they are largely there bar final sign off from our providers, which we do not anticipate to be a major problem.

The guidance issued last week by NHSE has introduced some delay into the process as we now need to update both of our policies to reflect the revised cohort of eligible patients – they are actually a bit different from the original RMOC criteria and are certainly wider.  I am sure you will agree that it would be improper to release guidance based on the RMOC criteria when these have been superseded with what we should probably term NHSE criteria.

As I am sure you are aware, although we have not formally released our guidance, our providers have been working to the documents and have started to make Flash Glucose Monitoring FlashGM available to patients under the RMOC criteria, which I am sure that Dr Narendran will confirm for you.  Up until now, we have classified FlashGM as ‘red’ meaning that the supply is done directly from the provider rather than by GP prescription, and so our national prescribing data will not reflect the true picture.  Going forward, it is highly likely that our initial assessment and initiation of FlashGM will be done in secondary care and prescribing transferred to primary care in four to six weeks after an interim assessment that the intervention is being used as per the guideline.  At this stage, I have no concerns about us meeting the April deadline for making FlashGM available.

To me, this is fascinating as they've seen that Red Listing is probably not the best way.  Up until this point, I'd always assumed BSol would red list.


The final policy is here.

Comments

Popular posts from this blog

Abbott dX 2022 Barcelona - "Make it Count"

For the past four years I've been invited by Abbott to a conference bringing together people with diabetes from across Europe to discuss various topics.  The first year I was meant to attend, it was my 'man v horse' year (the horse won!), so was unable to attend and then the pandemic hit so two further dX's were held virtually.  I was fortunate to be asked to present at last year's session.  This year's event was back in-person and held in Barcelona, coinciding with the latter part of the ATTD conference.   At this point, I must make it very clear - Abbott invited me to the 2022 European Diabetes Exchange forum (dX), that took place in Barcelona.  I attended this two-day event to connect and interact with inspirational and influential people in the diabetes community.  Abbott paid for my ticket and accommodation. #InvitedbyAbbott.  This is formal and it needs to be - I have not been required to do anything by Abbott as a result of my attendance and I hope that m

The CCG Project!

In order to find out the situation around the country for Libre prescribing now that the national policy has been published, I have made the decision to contact many of them to find out their plans.  I have arbitrarily chosen to contact all English CCGs that in December 2018 prescribed Libre via Primary Care to less than 5% of their population (and one specific request from a group member).  I had hoped this would be a small list, but there are 135 CCGs on the list.  I may have bitten off more than I can chew, but I'm committed to doing this and feeding back.  It worked before and hopefully this level of scrutiny will bring similar results. Below is a screenshot of the base document I am sending to each of the CCGs - it has some fields that are merge fields, so don't worry about the brackets and codes in the document (I found a typo, which has now been corrected too) .  The major piece of work with respect to this is finding the right person to contact.  However, I have s

July Update - CCGs Under Pressure!

The heat is unbearable in some parts, not only in the environment, but also hopefully the heat directed at the decision-makers in 'non-compliant' CCGs who are either refusing to accept that Libre is a revolutionary tool for many T1s or have agreed to fund, but then set crippling criteria. Latest Prescribing Data Progress in prescribing continues, with stabilisation in Scotland and a continuation of the steady rise in the other three countries of the UK.  The Wales May data should be out this week. As mentioned last month, the situation in Scotland is particularly promising and the excellent Edinburgh Centre for Endocrinology and the Scottish Health Technologies Group have published documents that should significantly help the Libre case.  These documents are based on the first six months of prescribing Libre. Healthcare Improvement Scotland Statement Flash Glucose Monitoring is associated with improved glycaemic control and quality of life in people with type 1 d